Clinical trials: Mixed Mania
Bipolar-I Disorder With Mania or Mania With Mixed Features
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
The purpose of this study is to evaluate the efficacy and safety of KarXT for the treatment of manic episodes in Bipolar-I Disorder
- Trial name
- BALSAM-1 (NCT06951698)
- Testing
- KarXT
- Where
- 74 sites in United States, Argentina and 7 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Bipolar Disorder Type I With Mania or Mania With Mixed Features
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, inpatient study in participants with bipolar disorder experiencing an acute episode of mania or mania with mixed features.
- Trial name
- NCT06951711
- Testing
- KarXT
- Where
- 85 sites in United States, China and 9 more
- Volunteers
- 274 people
- Sponsor
- Bristol-Myers Squibb
Bipolar Disorder, Mania
Allopurinol Maintenance Study for Bipolar Disorder
The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for the prevention of mania in bipolar disorder patients with currently stable mood.
- Conditions
- Bipolar Disorder, Mania, Mixed Mania
- Trial name
- NCT00732251
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Cedars-Sinai Medical Center
Bipolar Disorder, Mixed Mania
Allopurinol Add-on Treatment for Refractory Mania
The purpose of this study is to investigate the efficacy of allopurinol as an augmentation agent for treatment resistant mania and mixed mania.
- Conditions
- Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
- Trial name
- NCT00643123
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Cedars-Sinai Medical Center
Adolescent Schizophrenia, Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features
Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.
This is an open-label study consisting of a screening period, a conversion/titration phase (Phase 1), an open-label treatment phase (Phase 2), and a follow-up period.
- Trial name
- ATTAIN 267 (NCT01122927)
- Testing
- Aripiprazole
- Where
- 101 sites in United States, Bulgaria and 11 more
- Volunteers
- 524 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Bipolar, Mania, Bipolar, Mixed State
Prazosin as an Antimanic Agent in Severe Mania or Mixed States
Mania has been considered to be, in part, a hyperadrenergic state. One focus of treatment of mania involves directly targeting this hyperexcitable state by reducing arousal with antiadrenergic agents.
- Trial name
- NCT01621165
- Testing
- Addition of prazosin to usual care (add-on study)
- Sponsor
- Mclean Hospital
Manic or Mixed Episode Associated With Bipolar I Disorder
Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder
The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC [Study BMAC]) will be examined.
- Trial name
- NCT00266630
- Testing
- olanzapine, lithium, valproate
- Where
- 11 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Eli Lilly and Company
Mixed Mania Bipolar Disorder
Six Month Trial of Lamotrigine vs. Sodium Valproate for Treatment of Mixed Mania
We are comparing the efficacy of Lamotrigine to that of Standard of Care Sodium Valproate for the treatment of Mixed Mania. The study hypothesis is that Lamotrigine will be more efficative for treating mixed mania in patients…
- Trial name
- NCT00206778
- Testing
- Lamotrigine, Sodium Valproate
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Beth Israel Medical Center
Bipolar Disorder With Manic or Mixed Episodes
Safety and Efficacy of MEM 1003 Versus Placebo for the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to establish the potential of MEM 1003 as a safe and effective treatment for patients with an acute manic or mixed episode of bipolar disorder.
- Trial name
- NCT00374920
- Testing
- MEM 1003
- Where
- 21 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memory Pharmaceuticals
Mania, Mixed Mania
A Comparison Study of the Efficacy and Tolerability of Depakote ER and Depakote DR
To compare the time to response, response rates, remission rates, and side effects in Bipolar Disorder inpatients treated with Depakote ER or Depakote DR for acute mania or mixed mania.
- Trial name
- NCT00334347
- Testing
- Depakote ER, Depakote DR
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Massachusetts General Hospital
Bipolar I Disorder, Manic or Mixed
Evaluate the Safety of Depakote Extended Release Tablets in the Treatment of Mania Associated With Bipolar Disorder in Children and Adolescents
To determine if long-term treatment, up to 6 months, with Depakote ER is safe and effective in the treatment of bipolar I disorder in children and adolescents.
- Trial name
- NCT00195767
- Testing
- divalproex sodium
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Abbott